

HR 235

Triple-Negative Breast Cancer Research and Education Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 10, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 20, 2023)

Official Text: https://www.congress.gov/bill/118th-congress/house-bill/235

Sponsor

Name: Rep. Jackson Lee, Sheila [D-TX-18]

Party: Democratic • State: TX • Chamber: House

Cosponsors (12 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moore, Gwen [D-WI-4]	D · WI		Oct 10, 2023
Rep. Bacon, Don [R-NE-2]	R · NE		Oct 11, 2023
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Oct 11, 2023
Rep. Tonko, Paul [D-NY-20]	D · NY		Oct 16, 2023
Rep. Williams, Nikema [D-GA-5]	D · GA		Oct 18, 2023
Rep. Ivey, Glenn [D-MD-4]	D · MD		Oct 25, 2023
Rep. Evans, Dwight [D-PA-3]	D · PA		Oct 26, 2023
Rep. Carter, Troy [D-LA-2]	D · LA		Nov 6, 2023
Rep. Jackson, Jonathan L. [D-IL-1]	D · IL		Mar 21, 2024
Rep. Moskowitz, Jared [D-FL-23]	D · FL		Mar 26, 2024
Rep. Cherfilus-McCormick, Sheila [D-FL-20]	D · FL		Jul 15, 2024
Rep. Sewell, Terri A. [D-AL-7]	D · AL		Jul 15, 2024

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 20, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

## **Triple-Negative Breast Cancer Research and Education Act of 2023**

This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors.

Specifically, the National Institutes of Health must conduct and support research into the disease.

Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.

## **Actions Timeline**

---

- **Jan 20, 2023:** Referred to the Subcommittee on Health.
- **Jan 10, 2023:** Introduced in House
- **Jan 10, 2023:** Referred to the House Committee on Energy and Commerce.